Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy

Falagas, 2005, Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections, Clin Infect Dis, 40, 1333, 10.1086/429323

Gales, 2011, Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–2009), J Antimicrob Chemother, 66, 2070, 10.1093/jac/dkr239

Kwa, 2007, similarities to and differences from colistin (polymyxin E), Expert Rev Anti Infect Ther, 5, 811, 10.1586/14787210.5.5.811

Van Biesen, 2006, Defining acute renal failure: RIFLE and beyond, Clin J Am Soc Nephrol, 1, 1314, 10.2215/CJN.02070606

Bellomo, 2004, Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group, Crit Care, 8, R204, 10.1186/cc2872

Hartzell, 2009, Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center, Clin Infect Dis, 48, 1724, 10.1086/599225

Kwon, 2010, Predictors of acute kidney injury associated with intravenous colistin treatment, Int J Antimicrob Agents, 35, 473, 10.1016/j.ijantimicag.2009.12.002

Pogue, 2011, Incidence of and risk factors for colistin-associated nephrotoxicity in a large Academic health system, Clin Infect Dis, 53, 879, 10.1093/cid/cir611

Holloway, 2006, Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit, Ann Pharmacother, 40, 1939, 10.1345/aph.1H353

Ramasubban, 2008, Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock, Indian J Crit Care Med, 12, 153, 10.4103/0972-5229.45074

Pastewski, 2008, Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series, Ann Pharmacother, 42, 1177, 10.1345/aph.1K346

Oliveira, 2009, Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity, Diagn Microbiol Infect Dis, 65, 431, 10.1016/j.diagmicrobio.2009.07.018

Mendes, 2009, Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use, Ann Pharmacother, 43, 1948, 10.1345/aph.1M277

Elias, 2010, The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic, J Antimicrob Chemother, 65, 2231, 10.1093/jac/dkq285

Kvitko, 2011, Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia, J Antimicrob Chemother, 66, 175, 10.1093/jac/dkq390

Marik, 2002, Definition of sepsis: not quite time to dump SIRS?, Crit Care Med, 30, 706, 10.1097/00003246-200203000-00039

Thom, 2008, Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points, Infect Control Hosp Epidemiol, 29, 1048, 10.1086/591453

Rattanaumpawan, 2011, Risk factors for colistin-associated nephrotoxicity, J Infect, 62, 187, 10.1016/j.jinf.2010.11.013

Kim, 2009, Clinical characteristics and risk factors of colistin-induced nephrotoxicity, Int J Antimicrob Agents, 34, 434, 10.1016/j.ijantimicag.2009.06.028

Jeffres, 2007, A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia, Clin Ther, 29, 1107, 10.1016/j.clinthera.2007.06.014

Lodise, 2008, Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity, Antimicrob Agents Chemother, 52, 1330, 10.1128/AAC.01602-07

Garonzik, 2011, Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients, Antimicrob Agents Chemother, 55, 3284, 10.1128/AAC.01733-10

Plachouras, 2009, Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria, Antimicrob Agents Chemother, 53, 3430, 10.1128/AAC.01361-08

Zavascki, 2008, Pharmacokinetics of intravenous polymyxin B in critically ill patients, Clin Infect Dis, 47, 1298, 10.1086/592577

Kwa, 2008, Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections, Diagn Microbiol Infect Dis, 60, 163, 10.1016/j.diagmicrobio.2007.08.008

Kwa, 2011, Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report, Clin Infect Dis, 52, 1280, 10.1093/cid/cir137

Deryke, 2010, Colistin dosing and nephrotoxicity in a large community teaching hospital, Antimicrob Agents Chemother, 54, 4503, 10.1128/AAC.01707-09